Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that a specific genetic variant in the INSR gene is linked to severe insulin resistance and hyperandrogenemia in type A insulin resistance syndrome, suggesting the benefit of exon sequencing for accurate diagnosis and treatment.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This Delphi study found that moderate-to-severe alopecia areata in Poland, Czechia, Russia, and Türkiye significantly impacts quality of life and highlights an unmet need for more effective treatments.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

In this case report, researchers described a 6-year-old girl with severe mandibuloacral dysplasia type A, noting unique physical deformities and a rare homozygous LMNA gene mutation not commonly associated with the condition.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

Deuruxolitinib is generally safe for treating alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

This study found that among placebo-treated patients in the BRAVE-AA trials, the likelihood of spontaneous hair regrowth in untreated severe alopecia areata was low, with only a small percentage achieving significant scalp, eyebrow, or eyelash hair improvement over 36 weeks.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This case report describes a 37-year-old female with non-classical congenital adrenal hyperplasia who presented with severe acne, progressive hair loss, and primary infertility, managed with prednisolone.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.